Abstract | BACKGROUND: PURPOSE: DESIGN: Retrospective interventional case series. PARTICIPANTS: Six eyes of five patients with MFC-associated CNV were treated with intravitreal bevacizumab and/or ranibizumab. MAIN OUTCOME MEASURES: Visual acuity at 1, 3, and 6 months after the initial injection. RESULTS: Previous therapies (number of eyes treated) included sub-Tenon's corticosteroids (2), intravitreal corticosteroids (1), photodynamic therapy (1), and thermal laser (1). The mean number (range) of antivascular endothelial growth factor injections per eye was 2.3 (1-6). The mean duration (range) of follow-up per patient was 41.5 (25-69) weeks. Five of six eyes improved to 20/30 acuity or better at 6 months. One eye suffered a subfoveal rip of the retinal pigment epithelium with 20/400 acuity. There was a qualitative decrease in clinical and angiographic evidence of CNV. CONCLUSIONS:
Bevacizumab and ranibizumab were effective at improving visual acuity over 6 months in a small series of patients with MFC-associated CNV. Tears of the retinal pigment epithelium may occur after intravitreal antivascular endothelial growth factor therapy in MFC-associated CNV.
|
Authors | Howard F Fine, Inna Zhitomirsky, K Bailey Freund, Gaetano R Barile, Belinda L Shirkey, C Michael Samson, Lawrence A Yannuzzi |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 29
Issue 1
Pg. 8-12
(Jan 2009)
ISSN: 1539-2864 [Electronic] United States |
PMID | 18784620
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Vascular Endothelial Growth Factor A
- Bevacizumab
- Ranibizumab
|
Topics |
- Adult
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Choroidal Neovascularization
(drug therapy, etiology)
- Choroiditis
(complications, drug therapy)
- Drug Therapy, Combination
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Humans
- Injections
- Male
- Middle Aged
- Ranibizumab
- Retrospective Studies
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
- Vitreous Body
|